8-K: INmune Bio Bolsters Stock Incentive Plan and Unveils Promising Alzheimer's Drug Data

INmune Bio Inc. announced stockholder approval to significantly increase shares under its stock incentive plan and reported positive preclinical results for its XPro drug candidate in an animal model of Alzheimer's disease linked to traumatic brain injury.

Summary

• INmune Bio Inc. held its annual meeting of stockholders on June 10, 2025, where several key proposals were approved.
• Stockholders approved the Second Amended and Restated 2021 Stock Incentive Plan, increasing the number of shares issuable under the plan from 4,000,000 to 6,500,000 shares and permitting the acceleration of vesting awards upon a change of control.
• The company's directors, Raymond J. Tesi, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen, were elected to hold office until the next annual meeting.
• The appointment of CBIZ CPAs P.C. as the independent auditors for the fiscal year ending December 31, 2025, was ratified by stockholders.
• Stockholders approved, by a non-binding advisory vote, the compensation of the company's named executive officers.
• A non-binding advisory vote determined that the frequency of future advisory votes on named executive officer compensation will be every three years.
• INmune Bio announced a collaboration with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University, focusing on the interaction of traumatic brain injury (TBI) and Alzheimer's disease (AD).
• Preclinical study results, presented at the Keystone Symposias Neurodegeneration section, demonstrated that administration of XPro (XPro1595, pegipanermin) significantly reduced amyloid formation and improved clinical measures of brain function in an animal model of TBI-induced AD.
• The study showed that TBI triggered a transient increase in TNFR1, BACE1, and A42 expression in the hippocampus, and XPro inhibited these elevations, reducing intracellular neuronal amyloid accumulation and improving neurological outcomes.

Sentiment

Score: 8

Explanation: The document presents positive developments with the expansion of the stock incentive plan and, more significantly, promising preclinical results for XPro in a critical disease area (TBI-induced Alzheimer's). The collaboration and DoD support add credibility. While risks inherent to clinical-stage biotech are noted, the overall tone and content are favorable, suggesting progress and potential.

Positives

• Stockholders approved an increase of 2,500,000 shares for the 2021 Stock Incentive Plan, from 4,000,000 to 6,500,000, which can help attract and retain key talent.
• The Amended Plan now permits acceleration of vesting awards upon a change of control, providing additional incentive and security for award holders.
• Positive preclinical data for XPro (XPro1595, pegipanermin) demonstrated significant reduction in amyloid formation and improved brain function in an animal model of TBI-induced Alzheimer's disease, highlighting its therapeutic potential.
• The collaboration with Virginia Commonwealth University and support from the Department of Defense for the TBI and AD research provides external validation and potential for further funding.
• XPro's mechanism of action, selectively neutralizing soluble TNF without affecting trans-membrane TNF, suggests a targeted approach to neuroinflammation with potentially fewer side effects.

Risks

• Clinical trials for XPro1595 (XPro, pegipanermin), INKmune, and CORDStrom are in early stages, and there is no assurance that any specific outcome will be achieved or that they will be approved by the US Food and Drug Administration (FDA) or any regulatory body.
• There are risks and uncertainties relating to the Company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies, and future product commercialization is a significant risk.
• The Company faces risks and uncertainties related to its business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

The company's forward-looking statements indicate ongoing clinical trials for XPro1595, INKmune, and CORDStrom, with no assurance of specific outcomes or regulatory approvals. Future operations, research, development, clinical studies, and product commercialization are dependent on the availability of substantial additional funding.

Management Comments

• "Our findings demonstrate that TBI exacerbates amyloidogenesis and behavioral deficits in the hippocampus through solTNF/TNFR1 signaling. These results support XPro as a promising treatment to reduce AD pathology risk post-TBI and elucidate a key cellular mechanism linking inflammation to neurodegeneration." Dr. Kirsty Dixon, Assoc Prof. of Surgery at Virginia Commonwealth University.
• "An important feature of these findings is that XPro targets neurobehavioral dysfunction resulting from brain trauma and age-related neurodegenerative disease, which holds great promise for people suffering from these disorders." Elliott Mufson, PhD, professor of neurobiology, Barrow Neurological Institute.
• "Traumatic brain injury from falls is a significant concern for the elderly population at risk for Alzheimers disease, as it accelerates dementia onset. Effectively treating the resulting CNS pathology is critical to preserving cognitive function in this vulnerable group." RJ Tesi, MD, CEO of INmune Bio.

Industry Context

The collaboration between INmune Bio and Virginia Commonwealth University, supported by the Department of Defense, positions XPro as a potential therapeutic for Alzheimer's disease, particularly in the context of traumatic brain injury, a significant risk factor. This aligns with a growing industry focus on neuroinflammation as a key driver of neurodegenerative diseases and the development of targeted immunotherapies. The selective neutralization of soluble TNF by XPro differentiates it from broader TNF inhibitors, potentially offering a more precise approach to mitigate neuroinflammation without affecting beneficial TNF pathways.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies, projects, or results within the industry. The preclinical data for XPro in an animal model of TBI-induced Alzheimer's disease is presented as a promising finding, but no direct benchmarks against competitor drug candidates or established treatments are detailed.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from the increased share pool for the stock incentive plan, but also potential long-term value creation if the incentive plan aids in retaining key talent and the drug development programs succeed. The triennial say-on-pay vote frequency provides less frequent direct input on executive compensation.
• Employees/Management: Benefits from an expanded stock incentive plan with more shares available for awards and accelerated vesting upon a change of control, enhancing compensation and retention incentives.
• Patients/Medical Community: The positive preclinical results for XPro in TBI-induced Alzheimer's disease offer potential hope for a new therapeutic approach in a significant unmet medical need.
• Research Partners: The collaboration with Virginia Commonwealth University strengthens research efforts and leverages external expertise and funding (DoD support).

Next Steps

• Continue clinical trials for XPro1595, INKmune, and CORDStrom.
• Hold an advisory vote on executive compensation every three years until the next required say-on-frequency vote.

Key Dates

Recommendation

Keywords

INmune Bio, INMB, SEC filing, 8-K, Stock Incentive Plan, Alzheimer's disease, Traumatic Brain Injury, TBI, XPro1595, pegipanermin, neuroinflammation, amyloid, biotechnology, clinical-stage, innate immune system, corporate governance, executive compensation, stock options, biopharma